Onxeo (EU: ONXEO)

Last close As at 17/07/2024

EUR0.33

−0.01 (−2.94%)

Market capitalisation

EUR37m

Latest Insights

View More

Healthcare | edison tv

Onxeo – Edison Open House interview

Healthcare | edison tv

Onxeo – executive interview

Healthcare | Update

Onxeo — Progress with both REVOCAN and DRIIV-1b trials

Healthcare | Update

Onxeo — Expanding AsiDNA R&D programme

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 1.7 (3.4) (41.5)
Relative (6.8) (6.6) (38.8)
52 week high/low €0.6/€0.3

Financials

Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed Pharmaceuticals (INM), Onxeo (ONXEO), Arcane Crypto (ARCANE) and Aberdeen Diversified Income and Growth Trust (ADIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2019A 4.3 (9.1) (11.5) (14.98) N/A N/A
2020A 1.8 (7.2) (8.2) (12.26) N/A N/A
2021E N/A N/A N/A N/A N/A N/A
2022E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Onxeo — Expanding AsiDNA R&D programme

Flash note

Healthcare

Onxeo — First Phase Ib DRIIV results released

Outlook

Healthcare

Onxeo — Next generation of DNA damage repair inhibitors

Outlook

Healthcare

Onxeo — Introducing platON; AsiDNA approaches Phase I

Flash note

Healthcare

Onxeo — First significant milestone with AsiDNA achieved

Further insights

insight

Healthcare

DNA damage repair inhibitors

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free